

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of groups n = 5

EQA round: AP2/18 - Antithrombotic Agents

Dead line: 14.09.2018

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability					
							AV	U _{AV}	D _{max}	LL	UL	N _{eva}

Set of samples 1

(108) Apixaban	[µg/L]	21								21	20	95%	
Samples and groups													
Sample A1	202	19	9,3	21	CVP	202	10	25%	151	253	21	20	95%
(2) Chromogenous substrat	202	19	9,3	21	0						21		
Sample B1	422	19	4,6	21	CVP	422	10	25%	316	528	21	21	100%
(2) Chromogenous substrat	422	19	4,6	21	0						21		

Set of samples 2

(109) Dabigatran	[µg/L]	26								26	26	100%	
Samples and groups													
Sample A2	298	27	9,0	26	CVP	298	13	25%	223	373	26	26	100%
(1) Coagulometer	305	21	6,7	21	0						21		
(2) Chromogenous substrat	263	14	5,4	5	0						5		
Sample B2	100	12	12	26	CVP	100	5,9	25%	75	125	26	26	100%
(1) Coagulometer	102	9,3	9,2	21	0						21		
(2) Chromogenous substrat	87,0	7,4	8,5	5	0						5		

Set of samples 3

(110) Rivaroxaban	[µg/L]	31								31	28	90%	
Samples and groups													
Sample A3	298	28	9,5	31	CVP	298	12	25%	223	373	31	31	100%
(2) Chromogenous substrat	298	28	9,5	31	0						31		
Sample B3	93,3	14	15	31	CVP	93,3	6,2	25%	69,9	117	31	28	90%
(2) Chromogenous substrat	93,3	14	15	31	0						31		

st_kn_p

End of report

Printed: 20.09.2018